# US 2019/0315851 A1 · Anti-angptl3 antibodies and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0315851 A1
- Document ID: US20190315851A1
- Status: Published application
- Kind: A1
- Application number: 16/435,032
- Filed: 2019-06-07
- Published: 2019-10-17
- Earliest claimed: 2011-06-17
- Assignees: Regeneron Pharmaceuticals, Inc.
- Applicants: Regeneron Pharmaceuticals, Inc.
- Inventors: Mark W. SLEEMAN; Viktoria GUSAROVA; Andrew J. MURPHY
- Web page: https://patentgrep.com/patent/US20190315851A1

## CPC

- C07K 16/22: against growth factors {; against growth regulators}
- A61K 31/455: Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 2039/505: {comprising antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A fully human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits or interferes with at least one activity of human angiopoietin-like protein 3 (hANGPTL3) is provided. The human anti-hANGPTL3 antibodies are useful in treating diseases or disorders associated with ANGPTL3, such as hyperlipidemia, hyperlipoproteinemia and dyslipidemia, including hypertriglyceridemia, hypercholesterolemia, chylomicronemia, and so forth. Furthermore, the anti-hANGPTL3 antibodies can be administered to a subject in need thereof to prevent or treat diseases or disorders, for which abnormal lipid metabolism is a risk factor. Such diseases or disorders include cardiovascular diseases, such as atherosclerosis and coronary artery diseases; acute pancreatitis; nonalcoholic steatohepatitis (NASH); diabetes; obesity; and the like.

## Claims

### Claim 1

An isolated human antibody or antigen-binding fragment thereof that specifically binds human angiopoietin-like protein 3 (hANGPTL3) of SEQ ID NO: 161 and neutralizes, reduces or interferes with, at least one activity of hANGPTL3, wherein: (a) the antibody or antigen-binding fragment comprises a heavy chain variable region (HCVR) with at least 90% identity to SEQ ID NO: 66 and a light chain variable region (LCVR) with at least 90% identity to SEQ ID NO: 74; and/or (b) the antibody or antigen-binding fragment comprises a heavy chain variable region (HCVR) of SEQ ID NO: 66 with 10 or fewer conservative amino acid substitutions and a light chain variable region (LCVR) of SEQ ID NO: 74 with 10 or fewer conservative amino acid substitutions.

### Claim 2 (depends on 1)

The antibody or antigen-binding fragment thereof of claim 1, wherein:
(a) the HCVR has at least 95% identity to SEQ ID NO: 66 and/or the LCVR has at least 95% identity to SEQ ID NO: 74; or
(b) the HCVR has at least 98% identity to SEQ ID NO: 66 and/or the LCVR has at least 98% identity to SEQ ID NO: 74.

### Claim 3 (depends on 1)

The antibody or antigen-binding fragment thereof of claim 1, which comprises a HCVR of SEQ ID NO: 66 with eight or fewer, six or fewer, four or fewer or two conservative amino acid substitutions and/or a LCVR of SEQ ID NO: 74 with eight or fewer, six or fewer, four or fewer or two conservative amino acid substitutions.

### Claim 4 (depends on 1)

The antibody or antigen-binding fragment thereof of claim 1, which comprises a HCVR of SEQ ID NO: 66 with one addition, deletion or substitution and/or a LCVR of SEQ ID NO: 74 with one addition, deletion or substitution, optionally wherein the substitution(s) are conservative amino acid substitutions.

### Claim 5 (depends on 1)

The antibody or antigen-binding fragment thereof of claim 1, which comprises a HCDR1/HCDR2/HCDR3/LCDR1/LCDR2/LCDR3 sequence combination of SEQ ID NOS: 68/70/72/76/78/80.

### Claim 6

An isolated human antibody or antigen-binding fragment thereof that specifically binds human angiopoietin-like protein 3 (hANGPTL3) of SEQ ID NO: 161 and neutralizes, reduces or interferes with, at least one activity of hANGPTL3, wherein the antibody or fragment comprises a HCDR1/HCDR2/HCDR3/LCDR1/LCDR2/LCDR3 sequence combination of SEQ ID NOS: 68/70/72/76/78/80 with one or two conservative amino acid substitutions in any of the CDR sequences.

### Claim 7 (depends on 6)

The antibody of antigen-binding fragment of claim 6, which has one conservative substitution in one of the CDR sequences.

### Claim 8 (depends on 1, 6)

The antibody of antigen-binding fragment of claim 1 or 6, which exhibits biological activity which is essentially equivalent to an antibody comprising a HCVR/LCVR sequence pair of SEQ ID NOs: 66/74.

### Claim 9 (depends on 1)

The antibody or antigen-binding fragment of claim 1, wherein the antibody or fragment is a single chain antibody, an Fab, or an F(ab′)2.

### Claim 10 (depends on 1)

The antibody of claim 1, which is an IgG1 or IgG4.

### Claim 11 (depends on 1)

An isolated nucleic acid molecule encoding the antibody or fragment thereof of claim 1.

### Claim 12 (depends on 11)

An expression vector comprising the nucleic acid molecule of claim 11.

### Claim 13 (depends on 12)

An isolated host cell comprising the expression vector of claim 12.

### Claim 14 (depends on 13)

A method of producing an anti-hANGPTL3 antibody or antigen-binding fragment thereof, comprising growing the host cell of claim 13 under conditions permitting production of the antibody or fragment thereof, and recovering the antibody or fragment thereof so produced.

### Claim 15 (depends on 1)

A pharmaceutical composition comprising one or more antibodies or antigen-binding fragments thereof of claim 1 and a pharmaceutically acceptable carrier.

### Claim 16 (depends on 15)

The pharmaceutical composition of claim 15, further comprising one or more additional therapeutic agents selected from the group consisting of an inhibitor of HMG-CoA reductase, niacin, a fibrate, 22-hydroxycholesterol, ezetimibe plus simvastatin, a statin with a bile resin, niacin plus a statin, niacin plus an omega-3-fatty acid ethyl ester, a statin, an anti-hANGPTL4 antibody and an anti-PCSK9 antibody.

### Claim 17 (depends on 1)

A method for preventing or treating a disease or disorder which is prevented, ameliorated, improved, or inhibited by reduction or inhibition of ANGPTL3 activity, comprising administering to a subject the antibody or antigen-binding fragment thereof of claim 1.

### Claim 18 (depends on 17)

The method of claim 17, wherein the disease or disorder is selected from the group consisting of hypertriglyceridemia, hypercholesterolemia, which is optionally homozygous familial hypercholesterolemia with LDLR chylomicronemia, atherogenic dyslipidemia, mixed dyslipidemia, a cardiovascular disease or disorder, acute pancreatitis, nonalcoholic steatohepatitis (NASH), diabetes and obesity.

### Claim 19 (depends on 17)

The method of claim 17, further comprising administering to the subject one or more additional therapeutic agents selected from the group consisting of an inhibitor of HMG-CoA reductase, niacin, a fibrate, 22-hydroxycholesterol, ezetimibe plus simvastatin, a statin with a bile resin, niacin plus a statin, niacin plus an omega-3-fatty acid ethyl ester, a statin, an anti-hANGPTL4 antibody and an anti-PCSK9 antibody.

### Claim 20 (depends on 19)

The method of claim 19, wherein the antibody or fragment thereof and the one or more additional therapeutic agents are administered concurrently or sequentially to the subject.
